Teva Stories

Teva news, press releases, and media contact information

<< Back
Rutgers and Teva Join Forces in Support of Pharmaceutical Industry Fellowship Program
Biography Photo

Teva Regulatory Affairs is excited to be part of the Pharmaceutical Industry Fellowship Program at Rutgers University. We believe Teva offers a unique opportunity to gain experience in both generic and branded regulatory affairs in our facilities located in the suburban Philadelphia area.

In 2014, Teva and the Ernest Mario School of Pharmacy at Rutgers joined forces to provide fellows with unique opportunities to follow their passions into the pharmaceutical industry. Teva is the world’s largest generic pharmaceutical company, with over 600 Abbreviated New Drug Applications under active management in the US and a continuous stream of new applications.

This distinctive two-year program within our Global Regulatory Affairs team to enable an individual with a Doctor of Pharmacy degree to gain relevant, hands-on regulatory experience in a dynamic organization. The fellowship will be divided into two main segments:

  • Year 1 – devoted to work within the US Generics Regulatory Affairs team
  • Year 2 – allocated to work with the Global Branded Regulatory Affairs team in the US

This fellowship provides a unique blend of direct work experience with both generic and branded submission and approval processes, exposing the individual to similarities, differences, and comparative approaches between these two regulatory pathways. Overall, this experience provides the Fellow an opportunity to become a knowledgeable and contributing Regulatory Affairs professional.

Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE-accredited institution before July 1 of the fellowship term. Application materials may be submitted as early as November 17, and applicants are encouraged to submit as many of the required materials as possible by December 15.

For full information, please see the attached brochure.

Teva Fellowship Brochure